FAPI PET/CT in Gastric and Gastroesophageal Junctional Cancer
Status:
Not yet recruiting
Trial end date:
2034-09-01
Target enrollment:
Participant gender:
Summary
Twenty (n=20) patients with gastric cancer or gastro-esophageal junctional cancer will
undergo FAPI PET/CTs in addition to routing diagnostic workup (including FDG PET/CT) at
primary staging and restaging.
The FAPI PET/CT results will be compared to conventional imaging (including FDG PET/CT) using
histopathology as reference standard, and the diagnostic accuracy will be determined.
FAP-immunohistochemistry will be conducted in surgical specimens. FAPI PET/CT's impact on
patient management and the prognostic value of FAPI PET/CT will be evaluated.